Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer

Brief description of study

The purpose of the study is to obtain evidence of efficacy for maintenance selinexor in participants with advanced or recurrent endometrial cancer. Selinexor (KPT-330) is a small molecule, oral, first-in-class, potent selective inhibitor of nuclear export (SINE) compound. The study drug selinexor is investigational, which means that it has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test this agent in the current trial.




If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.